Clinical trial
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell…
NCT00069992 · Baylor College of Medicine, Other · Terminated
Key facts
| NCT number | NCT00069992 |
|---|---|
| Title | Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML |
| Official title | Safety And Efficacy of Sub-Myeloablative Allogeneic Stem Cell Transplantation For Patients With Myeloproliferative Disorder (MPD), Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML) or Chronic Myelogenous Leukemia |
| Acronym | MPDMDSBMT |
| Lead sponsor | Baylor College of Medicine, Other |
| Collaborators | The Methodist Hospital Research Institute Center for Cell and Gene Therapy, Baylor College of Medicine |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug, Radiation |
| Interventions | Total Body Irradiation, Fludarabine, Campath 1H |
| Enrollment | 7 |
| Start date | Dec 1, 2001 |
| Primary completion | Sep 1, 2006 |
| Completion | Apr 1, 2007 |
| First posted | Oct 7, 2003 |
| Last update posted | Oct 10, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: